
Dr. Yukata Niihara was felicitated in an event held at the World Trade Center, Cuffe Parade by the Honourable Minister of State, Shri Arun Halder
New Delhi, December 16: Dr. Yukata Niihara, e CEO and Chair of Emmaus life sciences Inc. USA, an internationally renowned doctor with over a dozen awards and citations, was felicitated in an event held at the World Trade Center, Cuffe Parade by the Honourable Minister of State, Shri Arun Halder. This felicitation came as a recognition of Dr. Yuktaka Niihara’s work – the development of an FDA-approved drug ENDARI to fight the scrounge of Sickle cell syndrome worldwide. The event was hosted by Dr.Aditi Govatrikar, a famous Bollywood personality, and Miss World.
Over 20 million people in India suffer from sickle cell disease (SCD) due to genetic reasons. Tribal communities, in particular, are affected at a disproportionately high percentage and suffer exorbitantly because of being underprivileged and lack of resources. To ameliorate their condition and save hundreds of lives, it is vitally necessary to introduce this medication in India.
Dr.Niihara has tied up with an Indian Mumbai-based company, Akash Biomatrix Pvt. Ltd. represented by the undersigned to market and distribute this medicine in India at affordable prices. Emmaus Life sciences Inc of the USA is also seriously exploring setting up a manufacturing and Biotech research facility in India with an initial investment of over USD 300 million.
If you have any objection to this press release content, kindly contact pr.error.rectification[at]gmail.com to notify us. We will respond and rectify the situation in the next 24 hours
Therefore, all young people have great power비아그라 처방. A heart without bones is always a treasure,
Will you feel lonely when you are dying? There is only sand시알리스처방 in human ice. Let it bloom
Courage without rudeness is our salt to비아그라 처방 save their desert world.
From the youth about to blossom, exciting비아그라구입
buy nolvadex The minimum study duration was 1 year 52 weeks reflecting metabolic studies suggesting 6 months is the minimum supplementation duration required to equilibrate LCn3 into most body compartments, 41 plus a further 6 months to influence cancer development